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ABSTRACT
Objectives: To investigate key patient clinical and
demographic characteristics associated with time
between colonoscopy and surgery, and choice of
treatment centre for colorectal cancer (CRC) patients.
This will add to the little published research examining
the pathway following CRC diagnosis and prior to
surgery.
Design: Retrospective cohort analysis of linked data.
Setting: A population-based sample of people
diagnosed August 2004 to December 2007 in New
South Wales, Australia.
Participants: 569 CRC patients, of whom 407 (72%,
95% CI 68% to 75%) had colonoscopy followed by
surgery.
Primary outcome measures: Time between
colonoscopy and surgery, and whether the surgery
took place in a specialist cancer centre.
Results: Among the 407 eligible patients analysed, the
median time from colonoscopy to surgery was 19 days
(IQR 12e29 days). After adjusting for key
demographic and clinical characteristics such as age
and disease stage, the time was longer for rectal
cancer patients and those reporting fair/poor health,
although differences in medians were <5 days. 24%
(95% CI 20% to 28%) had surgery in a specialist
cancer centre, which was more common among
people resident in metropolitan areas (37% vs 14% for
others, adjusted p¼0.001) and those without private
health insurance (30% vs 21% for others, adjusted
p¼0.03).
Conclusions: There do not appear to be systemic
issues affecting time from colonoscopy to surgery
related to patients’ socio-demographic characteristics.
However, patients with private insurance and those
living in rural areas may be less likely to receive
optimal specialist treatment. A more systematic
approach might be needed to ensure cancer patients
are treated in specialist cancer centres, particularly
patients requiring more specialised treatment.
INTRODUCTION
Despite the availability of clinical guidelines,
1
many colorectal cancer (CRC) patients do
not receive optimal care.
2 Two key aspects of
optimal cancer care are the time between
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ARTICLE SUMMARY
Article focus
- Investigate key patient clinical and demographic
characteristics associated with time between
colonoscopy and surgery, and choice of treat-
ment centre for colorectal cancer patients in New
South Wales, Australia.
- Most existing research has focused on delay
prior to diagnosis, and little is known about
factors associated with referral to specialist
treatment following diagnosis.
Key messages
- Rectal cancer cases had slightly longer time to
surgery than colon cancer cases.
- Treatment in a specialist cancer centre was
associated more with patient access than disease
characteristics.
- We need to ensure that those with the greatest
need, such as those with rectal cancer, have
access to timely and specialist treatment.
Strengths and limitations of this study
- This is one of the ﬁrst studies to examine the
pathway following colorectal cancer diagnosis
and prior to surgery, with a relatively large
population-based sample of patients.
- Surgery was the only treatment we could reliably
analyse.
- Surgeon specialties were not known so specialist
centres were identiﬁed as institutions with
radiotherapy facilities.
- We cannot determine the exact reason for longer
time to treatment and it might actually be
a positive,possiblyreﬂecting referralto a specialist
surgeon or preoperative radiotherapy.
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34and receiving treatment in
a specialist cancer centre.
5e8
A recent systematic review found a signiﬁcant rela-
tionship between hospital case volume and short-term
mortality for cancer patients who receive surgery.
9
However, inconsistencies in the ﬁndings mean that the
relative importance of surgeon volume and hospital
volume remains unclear and calls into question the
usefulness of using case volume alone.
9 Nevertheless,
treatment in a specialist cancer treatment centre is
important for patient care, especially for rectal cancer
cases.
5e8
The time between diagnostic procedures and treat-
ment is similarly important in terms of preventing
disease progression and limiting patient psychological
distress.
3 4 This may be compounded by delays in diag-
nosis. Patient variables such as age, sex or socioeconomic
status do not seem associated with delay. However, non-
recognition of symptom severity, symptom denial, having
a regular general practitioner prior to receiving a cancer
diagnosis, physician communication styles, receiving an
initial alternate diagnosis, misdiagnosis, inadequate
examination and inaccurate investigations all inﬂuence
diagnostic delay.
10 11 A recent prospective study reported
that 3-year mortality for CRC patients increased with
diagnostic delay beyond 1 month, particularly for those
presenting with serious symptoms.
12 Past studies have
also reported lower levels of CRC screening in Australia
among groups such as migrants and people living in
remote areas,
13e15 indicating potential for further diag-
nostic delay for these groups. In Australia, the National
Bowel Screening Program was introduced in 2006 with
one-off testing for people turning 55 or 65 years, with
people turning 50 years added in 2008.
16
The aim of this study was to use linked population-
based data to investigate factors associated with time
between colonoscopy and surgery and choice of treat-
ment centre for CRC cases in New South Wales (NSW),
Australia.
METHODS
Data sources
Data used for the study comprised linked records from
the population-based 45 and Up Study, the NSW Central
Cancer Registry (CCR), the NSW Admitted Patient Data
Collection (APDC) and claims for medical services from
Medicare Australia.
The 45 and Up Study is a general population cohort
study with over 265000 participants in NSW aged 45 years
or more, representing around 10% of the population of
that age. The study methods have been described in detail
elsewhere.
17 Brieﬂy, participants were randomly selected
from the Medicare Australia registration database, which
covers all citizens and permanent residents of Australia.
Baseline questionnaires were completed from January
2006 to April 2009, and participants gave consent to
linkage to health data collections including the CCR, the
APDC and Medicare claims records.
All cancers diagnosed in NSW, except for non-mela-
noma skin cancers, are notiﬁed to the NSW CCR. We
obtained CCR records for people diagnosed with CRC
between January 2001 and December 2007.
The NSW APDC contains information on all admitted
hospital episodes in NSW. Hospital medical coders
abstract individual patient information from medical
records following the patient’s discharge from hospital.
Data include dates of admission and separation, proce-
dures carried out and diagnoses relating to the hospital
episode. Procedures were coded using the Medicare
Beneﬁts Schedule-Extended classiﬁcation of the Inter-
national Classiﬁcation of Diseases 10th revision, Austra-
lian Modiﬁcation (ICD-10-AM). Up to 50 procedure
codes could be recorded for each episode. We used
hospital separation records from July 2000 to June 2008.
Medicare data comprised claims for medical services
through the Medicare Beneﬁts Scheme (MBS) between
June 2004 and January 2009. The MBS, a component of
Australia’s national health insurance system, provides
subsidised access to medical services for Australian resi-
dents.
Record linkage
Identifying information for participants in the 45 and
Up Study were linked with identiﬁers in the CCR, APDC
hospital records and MBS claims. The linkage to the
CCR and APDC was done by the Centre for Health
Record Linkage
18 (CHeReL) using probabilistic
matching carried out with ChoiceMaker software
(ChoiceMaker Technologies Inc.). Both certain and
uncertain matches were reviewed clerically, resulting in
approximately 0.1% false-positive and <0.1% false-
negative linkages. Linkage to MBS claims records was
done by the Sax Institute using an encrypted version of
the Medicare identiﬁcation number. Ethical approval for
the overall 45 and Up Study, this speciﬁc study and the
linkage was given by the University of NSW Human
Research Ethics Committee and the NSW Population
and Health Services Research Ethics Committee. The
provision of Medicare claims records was approved by
the Department of Health and Ageing Ethics
Committee.
Subjects
The group of interest comprised 45 and Up Study
participants diagnosed with CRC who had a colonoscopy
recorded in the APDC leading up to their diagnosis and
surgical treatment after diagnosis. We restricted the
sample to cases diagnosed from August 2004 to
December 2007 who linked to both the APDC and MBS,
so all cases had at least 2 months of treatments and
consultations recorded prior to diagnosis and for at least
6 months after diagnosis.
Socio-demographic and clinical characteristics
The 45 and Up Study data included self-reported data
regarding height, weight, highest education level
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Colorectal cancer treatment factorsattained, family history of CRC, smoking status, marital
status, housing type, country of birth, language spoken at
home, health insurance status (private with extras, private
no extras, Department of Veterans Affairs/Healthcare
card, none of these), income level (Australian dollars)
and health status. Body mass index was calculated as
weight (kilogram) divided by the square of height
(metre). The CCR provided data regarding month and
year of CRC diagnosis (the date of the most deﬁnitive
cancer notiﬁcation, likely to be based on the pathology
form for the specimen obtained via colonoscopy), age at
diagnosis, disease stage (classiﬁed as localised, regional
spread, distant metastases or unknown), cancer site and
local government area of residence at diagnosis from
which we assigned quintiles of socioeconomic disadvan-
tage. We identiﬁed patient comorbidities from APDC
diagnosis codes, including cardiovascular disease, chronic
obstructive pulmonary disease (COPD), diabetes and
other diseases in the Charlson Comorbidity Index
19
(‘other key comorbidities’).
Procedures and consultations
A specialist clinical panel (MFH, IO and MB) identiﬁed
relevant procedure codes and items for colonoscopies
and CRC surgery in the APDC and MBS data. Surgical
treatment comprised hemicolectomies, total colec-
tomies, partial colectomies, total proctocolectomies,
anterior rectal resections, Hartmann’s procedure
(rectosigmoidectomy), abdominoperineal resections
and ‘other’ resections of the colon or rectum. Chemo-
therapy and radiotherapy are generally performed on an
outpatient basis, for which data were not available, so
they were not included in the analysis.
Diagnosis dates were available as month and year only,
so chronology around diagnosis was based on calendar
month and year only. We included surgical procedures
from the month of diagnosis onwards and the last pre-
surgery colonoscopy no earlier than 2 months prior to
the month of diagnosis. Actual dates of colonoscopy
and surgery were used in analysing time between the
procedures.
Outcomes
The primary outcomes of interest were the time between
diagnosis and treatment and whether or not the patient
received surgery in a specialist cancer centre, as deﬁned
by an institution having radiotherapy facilities. Colono-
scopy was used as the indicator for diagnosis and an
appropriate surgical procedure as the treatment. Over
90% of the relevant colonoscopies and surgical proce-
dures were identiﬁed in the APDC, with just over half of
these also identiﬁed in the MBS. The remaining colo-
noscopies were recorded in the MBS only.
Statistical analysis
c
2 Tests were used to compare patient groups, and
unconditional multivariable logistic regression was used
to identify factors associated with treatment in
a specialist cancer centre. Cox’s proportional hazards
regression was used to investigate factors associated with
time between colonoscopy and surgery. Factors of
interest were patient characteristics including age,
disease stage, place of residence and self-reported health
status, as described in table 2. A small number of patients
with missing values for variables of interest were
excluded from analyses. All analyses were carried out in
SAS V.9.1 (SAS Institute Inc.).
RESULTS
Baseline questionnaire data from the 45 and Up Study
were received for the ﬁrst 102938 study participants,
with questionnaires completed between January 2006
and May 2008. These were linked to 1023 cases of CRC in
the CCR. Among these 1023 cases, 1007 (98%) linked to
at least one APDC hospital record and 985 (96%) linked
to at least one MBS claim in the available data. The 1023
were compared with all CRCs diagnosed in NSW
between 2001 and 2007 and a greater proportion of the
study sample was men (62% vs 54% overall), Australian
born (76% vs 70%), diagnosed in 2007 (22% vs 16%),
had localised stage of disease (42% vs 34%) or were
living in rural areas (34% vs 26%) or the two least
socioeconomically disadvantaged quintiles (50% vs
36%), while a lower proportion were aged 80 years or
more (15% vs 23%), had distant metastases (7% vs 17%),
had any of the key comorbidities (32% vs 41%) or were
living in metropolitan areas (41% vs 51%).
The sample was restricted to the 569 CRC cases diag-
nosed from August 2004 to December 2007 who linked
to both the APDC and MBS (ﬁgure 1). This represents
4% of all CRCs diagnosed in NSW between August 2004
and December 2007. We found that around 95% of
surgical cases had their surgery within 3 months of
diagnosis so the minimum 6 months of follow-up we
have for all cases is reasonable (average follow-up:
25 months).
Of the 569 cases diagnosed from August 2004 to
December 2007, 537 (94%) had a colonoscopy recorded
at any time and 488 (86%) had surgery. There were 407
(n=599, 59% of 1023)
45 and Up CRC cases diagnosed 2001–2007
(n=1023)
Diagnosed pre-August 2004
(n=424)
No link to APDC (n=8)
or MBS (n=22)
Link to APDC and MBS records
(n=569, 95% of 599)
Had colonoscopy  followed by surgery 
during/after month of diagnosis
(n=407, 72% of 569)
No surgery (n=81) or no earlier 
colonoscopy (n=81)
Diagnosed August 2004 to December 2007
Figure 1 Sample selection process. APDC, Admitted Patient
Data Collection; CRC, colorectal cancer; MBS, Medicare
Beneﬁts Scheme.
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diagnosis onwards and had a colonoscopy beforehand
(up to 2 months before the month of diagnosis). These
are the cases in whom we were most interested. Table 1
shows that these 407 cases were similar to the 616 cases
identiﬁed in the CCR but not included in the study,
except for a higher proportion with localised disease
(45% and 40%, respectively), who lived in metropolitan
areas at diagnosis (46% and 38%) or who were diag-
nosed with CRC after completing the 45 and Up Study
questionnaire (20% vs 10%).
Time between colonoscopy and surgery
The overall median time from colonoscopy to surgery
was 19 days (IQR 12e29 days). After adjusting for all
measured factors, the time from colonoscopy to surgery
was signiﬁcantly longer for cases with rectal cancer and
cases reporting fair/poor health (table 2). Given the
likely difference in treatment patterns for colon and
rectal cancer cases, we analysed them separately. Among
rectal cancer, there was shorter time to surgery for cases
with COPD, Department of Veterans Affairs/Healthcare
cards, good to excellent self-reported health, those living
in a house (compared with ﬂat/unit or elderly accom-
modation) and cases not living in rural areas (table 3).
For cases with colon cancer, who should not require
preoperative radiotherapy or chemotherapy, there were
no major differences in the time to surgery across the
subgroups compared. The period was marginally longer
for cases with unknown disease stage, those with lower
income and those with a comorbidity in the Charlson
Index other than cardiovascular disease, COPD or
Table 1 Characteristics of colorectal cancer cases included in the study and those not included in further analyses (n¼1023)
45 and Up cases diagnosed,
August 2004 to December
2007, had colonoscopy and
surgery (n[407)
All other 45 and Up cases
diagnosed, January 2001 to
December 2007 (n[616) p value
for difference No. of cases % of cases No. of cases % of cases
Sex 0.72
Female 152 37 237 38
Male 255 63 379 62
Age at diagnosis (years) 0.08
<60 78 19 135 22
60e69 108 27 193 31
70e79 150 37 208 34
80+ 71 17 80 13
Place of residence at diagnosis 0.02
Metropolitan 186 46 234 38
Other urban 103 25 156 25
Rural 118 29 226 37
Self-reported health status 0.58
Good to excellent 307 75 447 73
Fair/poor 78 19 134 22
Unspeciﬁed 22 5 35 6
Chronic obstructive pulmonary disorder* 0.20
Yes 29 7 32 5
No 378 93 568 95
Diabetes* 0.69
Yes 50 12 71 12
No 357 88 529 88
Cancer site 0.49
Colon 265 65 414 67
Rectum 142 35 202 33
Disease stage 0.003
Localised 185 45 246 40
Regional 176 43 255 41
Distant metastases 27 7 48 8
Unknown 19 5 67 11
Timing of colorectal cancer diagnosis relative to 45 and Up questionnaire <0.001
Before (prevalent) 327 80 552 90
After (incident) 80 20 64 10
No differences between groups for year of diagnosis, socioeconomic status, housing type, language other than English at home, country of
birth, highest education level attained, family history of colorectal cancer, body mass index, smoking status, marital status, health insurance,
income level, cardiovascular disease recorded in hospital or other diseases in the Charlson Comorbidity Index.
*Excludes 16 cases not linked to Admitted Patient Data Collection who did not have comorbidity information.
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Colorectal cancer treatment factorsTable 2 Demographic and clinical characteristics associated with time between colonoscopy and colorectal cancer surgery for
all colorectal cancer cases (n¼407)
n
Median
time (days) IQR (days)
Adjusted
HR (95% CI)*
Overall
p valuey
Sex 0.25
Female 152 19 12e28 1.18 (0.89 to 1.58)
Male 255 20 12e31 1.00 (ref)
Age (years) 0.88
<60 78 17 8e29 0.96 (0.68 to 1.37)
60e69 108 19 13e32 0.93 (0.69 to 1.26)
70e79 150 21 12e29 1.00 (ref)
80+ 71 20 12e28 1.10 (0.77 to 1.57)
Country of birth 0.64
Australia 320 19 13e29 1.00 (ref)
Other 81 19 8e30 0.93 (0.67 to 1.28)
Unknown 6 12 10e40 Not incl.
Non-English spoken at home 0.20
Yes 30 21 10e38 1.38 (0.84 to 2.27)
No 377 19 12e29 1.00 (ref)
Place of residence at diagnosis 0.56
Metropolitan 186 19 11e28 1.00 (ref)
Other urban 103 20 13e28 1.16 (0.77 to 1.74)
Rural 118 20 11e33 0.96 (0.65 to 1.43)
Type of housing 0.52
House 296 19 12e29 1.00 (ref)
Flat/unit 50 19 10e29 1.10 (0.77 to 1.59)
House on farm 28 21 12e48 0.77 (0.49 to 1.23)
Elderly accommodation 26 22 17e42 0.85 (0.52 to 1.37)
Other/unspeciﬁed 7 29 19e31 Not incl.
Socioeconomic status 0.44
Least disadvantaged quintile 143 17 11e28 1.00 (ref)
Quintile 2 64 20 12e34 0.88 (0.57 to 1.38)
Middle quintile 126 20 8e29 1.17 (0.76 to 1.80)
Quintile 4 58 22 14e33 0.92 (0.60 to 1.41)
Most disadvantaged quintile 16 22 14e27 1.32 (0.66 to 2.62)
Highest education level attained 0.59
No school certiﬁcate/other 48 20 14e31 0.99 (0.67 to 1.47)
School/intermediate certiﬁcate 102 22 16e33 1.00 (ref)
Higher school/leaving certiﬁcate 28 18 12e34 1.02 (0.63 to 1.65)
Trade/apprenticeship 56 18 13e28 1.43 (0.96 to 2.13)
Certiﬁcate/diploma 83 20 10e29 1.03 (0.74 to 1.43)
Uni degree or higher 80 16 8e36 1.02 (0.71 to 1.48)
Unspeciﬁed 10 13 3e22 Not incl.
Marital status 0.18
Married/living as married 288 18 11e28 1.00 (ref)
Single/divorced/separated 51 24 12e37 0.93 (0.64 to 1.36)
Widowed 65 22 17e34 0.72 (0.51 to 1.02)
Unspeciﬁed 3 20 9e21 Not incl.
Income level 0.06
<$20K p.a. 112 21 14e31 1.00 (ref)
$20Ke<$40K p.a. 83 21 13e31 0.97 (0.67 to 1.41)
$40Ke<$70K p.a. 62 18 9e35 0.92 (0.62 to 1.36)
$70K+ p.a. 52 13 8e29 1.59 (1.01 to 2.51)
Unspeciﬁed 98 19 13e28 1.30 (0.93 to 1.81)
Health insurance 0.51
Private with extras 190 18 9e28 1.00 (ref)
Private no extras 70 17 11e28 1.13 (0.83 to 1.55)
DVA/healthcare card 101 21 14e29 1.05 (0.77 to 1.44)
None of these 37 28 19e41 0.76 (0.50 to 1.15)
Missing 9 25 16e28 0.86 (0.40 to 1.86)
Continued
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Colorectal cancer treatment factorsdiabetes (table 3). Just over one-quarter of cases (27%)
had more than 28 days between colonoscopy and
surgery; this was more common for rectal cancer cases
(39% vs 21% of colon cases).
Treatment in a specialist cancer centre
Ninety-nine (24%) of the 407 cases had their surgery in
a specialist cancer centre. This was more frequent
a m o n gt h o s el i v i n gi nm e t r o p o l i t a na r e a s ,a sw e l la s
for cases without private health insurance, those with
one of the ‘other’ Charlson Index comorbidities
and cases who were married or living with a partner
(table 4). When all the factors of interest were included
in the logistic regression place of residence, health
insurance and other comorbidities remained signiﬁ-
cantly associated with treatment in a specialist centre.
Table 2 Continued
n
Median
time (days) IQR (days)
Adjusted
HR (95% CI)*
Overall
p valuey
Body mass index 0.15
Underweight/normal 155 18 10e28 1.00 (ref)
Overweight 157 20 12e35 0.80 (0.61 to 1.05)
Obese/morbidly obese 66 22 13e31 0.92 (0.65 to 1.30)
Null/not speciﬁed 29 19 11e29 0.62 (0.38 to 0.99)
Smoking status 0.52
Never-smoker 203 19 10e29 1.00 (ref)
Ever-smoker 204 19 12e30 1.08 (0.85 to 1.37)
Self-reported health status 0.02
Good to excellent 307 18 11e29 1.00 (ref)
Fair/poor 78 21 15e40 0.69 (0.51 to 0.95)
Unspeciﬁed 22 22 14e28 0.59 (0.35 to 1.02)
Cardiovascular disease 0.37
Yes 47 20 9e29 0.84 (0.57 to 1.23)
No 360 19 12e30 1.00 (ref)
Chronic obstructive
pulmonary disease
0.16
Yes 29 20 11e27 1.41 (0.87 to 2.27)
No 378 19 12e30 1.00 (ref)
Diabetes 0.93
Yes 50 26 14e36 1.02 (0.70 to 1.48)
No 357 19 11e29 1.00 (ref)
Other key comorbidity 0.25
Yes 56 20 12e29 1.22 (0.87 to 1.71)
No 351 19 12e30 1.00 (ref)
Family history of CRC 0.58
Yes 75 20 13e33 0.92 (0.69 to 1.23)
No 332 19 12e29 1.00 (ref)
Disease stage 0.18
Localised 185 19 13e29 1.00 (ref)
Regional 176 19 10e29 1.06 (0.84 to 1.35)
Distant metastases 27 20 12e39 0.65 (0.39 to 1.09)
Unknown 19 35 13e48 0.70 (0.40 to 1.23)
Cancer site <0.001
Colon 265 18 10e27 1.00 (ref)
Rectum 142 22 14e37 0.55 (0.43 to 0.71)
Year of diagnosis 0.88
2004 43 19 9e26 1.10 (0.72 to 1.67)
2005 113 19 12e29 0.98 (0.73 to 1.32)
2006 111 21 14e32 0.92 (0.69 to 1.23)
2007 140 18 11e32 1.00 (ref)
Timing of CRC diagnosis
relative to 45 and
Up questionnaire
0.23
Before (prevalent) 327 19 11e29 1.21 (0.89 to 1.66)
After (incident) 80 21 14e31 1.00 (ref)
*Adjusted for all other variables in this table. HR <1 indicates longer time between colonoscopy and surgery.
yOverall p value from proportional hazards regression (ref): reference category.
CRC, colorectal cancer; DVA, Department of Veterans Affairs; Not incl., this category was not included in proportional hazards regression.
6 Goldsbury D, Harris MF, Pascoe S, et al. BMJ Open 2012;2:e001070. doi:10.1136/bmjopen-2012-001070
Colorectal cancer treatment factorsThere was no association with cancer site (colon/
rectum).
The signiﬁcant factors were similar when colon and
rectal cancer cases were analysed separately, although for
colon cases, there were also higher odds of treatment in
a specialist centre for cases not born in Australia (39% vs
21% of Australian born) and those with distant or
unknown disease stage (31% vs 24% of locoregional).
Looking at all hospital records and not just episodes
involving CRC surgery, 41% of cases had any admission
recorded at a specialist cancer centre. Around half of all
surgical procedures took place in public hospitals, and
these comprised almost two-thirds of surgical procedures
in specialist cancer centres.
DISCUSSION
Rectal cancer cases had slightly longer time to surgery
than colon cancer cases, even after adjustment for
comorbidities, disadvantage and health status, but there
was no evidence that rectal cancer cases were more likely
to be treated at specialist cancer centres (those with
a radiotherapy unit). Treatment in a specialist cancer
Table 3 Demographic and clinical characteristics associated with time between colonoscopy and colorectal cancer surgery,
separately for colon and rectal cancer cases
Colon cancer (n[265) Rectal cancer (n[142)
Adjusted
HR* (95% CI)
Overall
p valuey
Adjusted
HR* (95% CI)
Overall
p valuey
Place of residence at diagnosis 0.77 0.01
Metropolitan 1.00 (ref) 1.00 (ref)
Other urban 1.19 (0.67 to 2.10) 1.55 (0.72 to 3.37)
Rural 1.21 (0.71 to 2.07) 0.47 (0.21 to 1.09)
Type of housing 0.49 0.002
House 1.00 (ref) 1.00 (ref)
Flat/unit 1.18 (0.74 to 1.87) 0.31 (0.12 to 0.82)
House on farm 1.65 (0.84 to 3.25) 0.43 (0.18 to 1.03)
Elderly accommodation 1.07 (0.55 to 2.11) 0.19 (0.06 to 0.61)
Other/unspeciﬁed Not incl. Not incl.
Income level 0.04 0.06
<$20K p.a. 1.00 (ref) 1.00 (ref)
$20Ke<$40K p.a. 0.77 (0.46 to 1.29) 0.59 (0.30 to 1.17)
$40Ke<$70K p.a. 0.93 (0.55 to 1.57) 0.43 (0.18 to 0.99)
$70K+ p.a. 1.85 (1.01 to 3.40) 0.54 (0.20 to 1.43)
Unspeciﬁed 0.98 (0.63 to 1.52) 1.24 (0.62 to 2.46)
Health insurance 0.12 0.02
Private with extras 1.00 (ref) 1.00 (ref)
Private no extras 0.80 (0.52 to 1.22) 1.79 (0.93 to 3.45)
DVA/healthcare card 0.67 (0.46 to 0.98) 3.33 (1.59 to 6.97)
None of these 0.53 (0.29 to 0.97) 1.29 (0.58 to 2.90)
Missing 0.42 (0.12 to 1.42) 0.99 (0.28 to 3.46)
Self-reported health status 0.10 0.004
Good to excellent 1.00 (ref) 1.00 (ref)
Fair/poor 0.64 (0.42 to 0.96) 0.44 (0.21 to 0.92)
Unspeciﬁed 0.95 (0.48 to 1.89) 0.23 (0.07 to 0.76)
Chronic obstructive pulmonary disease 0.26 0.004
Yes 1.39 (0.79 to 2.44) 6.39 (1.80 to 22.70)
No 1.00 (ref) 1.00 (ref)
Other key comorbidity 0.04 0.06
Yes 1.64 (1.03 to 2.59) 2.14 (0.97 to 4.75)
No 1.00 (ref) 1.00 (ref)
Disease stage 0.05 0.87
Localised 1.00 (ref) 1.00 (ref)
Regional 1.08 (0.79 to 1.47) 1.03 (0.64 to 1.66)
Distant metastases 0.53 (0.28 to 1.02) 1.39 (0.47 to 4.14)
Unknown 0.48 (0.24 to 0.97) 0.65 (0.17 to 2.50)
The variables not shown in the table were not associated with time to surgery for colon or rectal cancers. HR <1 indicates longer time between
colonoscopy and surgery.
*Adjusted for all other variables in this table, as well as for sex, age, country of birth, language spoken at home, socioeconomic status, education
level, marital status, body mass index, smoking status, cardiovascular disease, diabetes, family history of colorectal cancer, year of diagnosis
and diagnosis before/after completing study questionnaire.
yOverall p value from proportional hazards regression (ref): reference category.
DVA, Department of Veterans Affairs; Not incl., this category was not included in proportional hazards regression.
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Colorectal cancer treatment factorsTable 4 Demographic and clinical characteristics associated with receiving colorectal cancer surgery in a specialist cancer
centre (n¼407)
Total (n)
Treatment in a specialist
cancer centre, n (%)
Adjusted OR
(95% CI)*
Overall
p valuey
Sex 0.71
Female 152 27 (18) 0.87 (0.43 to 1.79)
Male 255 72 (28) 1.00 (ref)
Age (years) 0.78
<60 78 17 (22) 0.67 (0.28 to 1.63)
60e69 108 27 (25) 1.01 (0.48 to 2.10)
70e79 150 33 (22) 1.00 (ref)
80+ 71 22 (31) 1.13 (0.45 to 2.85)
Country of birth 0.14
Australia 320 68 (21) 1.00 (ref)
Other 81 29 (36) 1.79 (0.83 to 3.90)
Unknown 6 2 (33) Not incl.
Non-English spoken at home 0.25
Yes 30 10 (33) 0.50 (0.15 to 1.62)
No 377 89 (24) 1.00 (ref)
Place of residence at diagnosis 0.001
Metropolitan 186 68 (37) 1.00 (ref)
Other urban 103 18 (17) 0.27 (0.10 to 0.73)
Rural 118 13 (11) 0.14 (0.05 to 0.40)
Type of housing 0.07
House 296 65 (22) 1.00 (ref)
Flat/unit 50 20 (40) 2.52 (1.06 to 6.01)
House on farm 28 7 (25) 3.08 (0.95 to 10.01)
Elderly accommodation 26 7 (27) 1.78 (0.49 to 6.40)
Other/unspeciﬁed 7 0 Not incl.
Socioeconomic status 0.46
Least disadvantaged quintile 143 54 (38) 1.00 (ref)
Quintile 2 64 9 (14) 0.78 (0.27 to 2.29)
Middle quintile 126 26 (21) 1.23 (0.45 to 3.34)
Quintile 4 58 9 (16) 0.52 (0.18 to 1.49)
Most disadvantaged quintile 16 1 (6) 0.35 (0.03 to 3.88)
Highest education level attained 0.16
No school certiﬁcate/other 48 14 (29) 3.69 (1.31 to 10.36)
School/intermediate certiﬁcate 102 16 (16) 1.00 (ref)
Higher school/leaving certiﬁcate 28 6 (21) 1.10 (0.29 to 4.24)
Trade/apprenticeship 56 15 (27) 1.84 (0.69 to 4.94)
Certiﬁcate/diploma 83 23 (28) 2.34 (0.96 to 5.68)
Uni degree or higher 80 23 (29) 1.69 (0.64 to 4.47)
Unspeciﬁed 10 2 (20) Not incl.
Marital status 0.10
Married/living as married 288 75 (26) 1.00 (ref)
Single/divorced/separated 51 12 (24) 0.53 (0.21 to 1.35)
Widowed 65 12 (18) 0.39 (0.15 to 1.01)
Unspeciﬁed 3 0 Not incl.
Income level 0.74
<$20K p.a. 112 27 (24) 1.00 (ref)
$20Ke<$40K p.a. 83 15 (18) 1.23 (0.47 to 3.24)
$40Ke<$70K p.a. 62 17 (27) 1.45 (0.54 to 3.91)
$70K+ p.a. 52 19 (37) 2.10 (0.71 to 6.19)
Unspeciﬁed 98 21 (21) 1.33 (0.56 to 3.16)
Health insurance 0.03
Private with extras 190 44 (23) 1.00 (ref)
Private no extras 70 10 (14) 0.72 (0.29 to 1.77)
DVA/healthcare card 101 29 (29) 2.17 (0.97 to 4.89)
None of these 37 12 (32) 2.75 (0.99 to 7.62)
Missing 9 4 (44) 7.41 (1.17 to 47.04)
Continued
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Colorectal cancer treatment factorscentre seems associated more with patient access than
disease characteristics as the only strongly signiﬁcant
factor was residing in a non-metropolitan area. These
results add further evidence for the disadvantage suffered
by rural people in terms of their access to cancer treat-
ment and are consistent with ﬁndings from New Zealand
for the Maori population.
20 Poor access may be one
contributing factor to poorer cancer survival.
21 22
The longer time from colonoscopy to surgery for
rectal cancer cases compared with colon cancer cases is
not necessarily a negative ﬁnding, given the additional
importance of specialist treatment for rectal cancer. It
may reﬂect referral to a CRC surgeon rather than
a general surgeon, assessment by a multidisciplinary
team, or the use of, or a referral for assessment for,
preoperative radiotherapy for rectal cancer, each of
which could lead to better patient outcomes. Further-
more, the crude difference in median time was only
4 days, which is not a clinically important difference in
terms of disease progression, although it might add to
Table 4 Continued
Total (n)
Treatment in a specialist
cancer centre, n (%)
Adjusted OR
(95% CI)*
Overall
p valuey
Body mass index 0.78
Underweight/normal 155 41 (26) 1.00 (ref)
Overweight 157 39 (25) 1.02 (0.53 to 1.97)
Obese/morbidly obese 66 12 (18) 0.80 (0.33 to 1.93)
Null/not speciﬁed 29 7 (24) 0.59 (0.18 to 1.97)
Smoking status 0.90
Never-smoker 203 45 (22) 1.00 (ref)
Ever-smoker 204 54 (26) 1.04 (0.57 to 1.89)
Self-reported health status 0.19
Good to excellent 307 77 (25) 1.00 (ref)
Fair/poor 78 17 (22) 0.55 (0.25 to 1.25)
Unspeciﬁed 22 5 (23) 0.36 (0.08 to 1.65)
Cardiovascular disease 0.61
Yes 47 13 (28) 0.78 (0.30 to 2.02)
No 360 86 (24) 1.00 (ref)
Chronic obstructive pulmonary disease 0.64
Yes 29 10 (34) 1.29 (0.44 to 3.82)
No 378 89 (24) 1.00 (ref)
Diabetes 0.15
Yes 50 17 (34) 1.88 (0.79 to 4.50)
No 357 82 (23) 1.00 (ref)
Other key comorbidity 0.04
Yes 56 19 (34) 2.43 (1.04 to 5.68)
No 351 80 (23) 1.00 (ref)
Family history of CRC 0.85
Yes 75 19 (25) 0.93 (0.44 to 1.96)
No 332 80 (24) 1.00 (ref)
Disease stage 0.55
Localised 185 41 (22) 1.00 (ref)
Regional 176 45 (26) 1.34 (0.72 to 2.47)
Distant metastases 27 9 (33) 2.02 (0.63 to 6.47)
Unknown 19 4 (21) 1.89 (0.44 to 8.20)
Cancer site 0.64
Colon 265 66 (25) 1.00 (ref)
Rectum 142 33 (23) 1.16 (0.63 to 2.16)
Year of diagnosis 0.11
2004 43 10 (23) 1.00 (0.36 to 2.80)
2005 113 24 (21) 0.40 (0.19 to 0.88)
2006 111 27 (24) 0.88 (0.43 to 1.81)
2007 140 38 (27) 1.00 (ref)
Timing of CRC diagnosis relative
to 45 and Up questionnaire
0.98
Before (prevalent) 327 76 (23) 1.01 (0.47 to 2.19)
After (incident) 80 23 (29) 1.00 (ref)
*Adjusted for all other variables in this table.
yOverall p value from logistic regression (ref): reference category.
CRC, colorectal cancer; DVA, Department of Veterans Affairs; Not incl., this category was not included in the logistic regression.
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Colorectal cancer treatment factorspatient distress. Analysis by disease site found that while
there were some statistically signiﬁcant differences in
time between colonoscopy and surgery, the median
differences were again in the order of a few days and
thus not critical to disease progression. However, we
should be mindful that these small delays may
compound delays in diagnosis for groups, such as
migrants and people living in remote areas who have
lower screening rates,
13e15 and that diagnostic delay is
associated with increased mortality for patients with
CRC.
12 The overall median time to surgery for all cases
was 19 days and this could also be important in the
context of additional delays along the total diagnostic
pathway. It is also worth noting the proportion of rectal
cases with more than a month between diagnosis and
surgery was almost double that of colon cases. This was
unrelated to issues such as private insurance but may be
related to the pathway for treatment prior to surgery,
including pre-surgical radiotherapy.
Treatment in a specialist cancer centre was associated
with place of residence, health insurance status and the
presence of comorbidities. Around one in four CRC
patients had their surgery in a specialist cancer centre,
while less than half were ever admitted to a specialist
cancer centre. The results suggest that access plays
a major role in place of treatment rather than the
potentially more important disease characteristics.
Rectal cancer patients in particular should be more
commonly treated at specialist cancer centres
5e7 or at
least be referred to a multidisciplinary team for consid-
eration for radiotherapy even if they are not in a radio-
therapy centre. Private patients may be at a disadvantage
in being referred to smaller private hospitals for their
surgical procedures.
The study has some limitations. Our initial plan was to
link CCR, APDC and MBS records for all CRC cases
diagnosed over a number of years, but MBS data could
not be released without the consent of each individual
and this was not feasible. Using the data from the 45 and
Up Study meant that the relevant consent had already
been given, but this might introduce some biases as
study participants are not representative of the popula-
tion due to people in rural areas being oversampled and
a possible ‘healthy volunteer’ effect. Our sample of
cancer patients represent 4% of all CRCs diagnosed in
NSW and were also more likely to be men, Australian
born and have localised disease. However, the study’s
population coverage was still reasonably broad and it has
been shown that the sample proﬁle does not substan-
tially impact on associations within the data.
23 Some of
the marginally statistically signiﬁcant associations may
have arisen by chance due to the large number of vari-
ables included in the analyses, but this is not likely to be
an explanation for associations with small p values.
Furthermore, we did not have access to surgeon
information or temporal surgeon specialty lists in the
almost 100 treating institutions included in the study, so
specialist cancer centres were identiﬁed as institutions
with radiotherapy facilities. We believe that our ﬁndings
address an important component of cancer treatment
and separate analyses of the distance from the treating
centre to radiotherapy facilities obtained similar results.
Treatment with chemotherapy or radiotherapy was not
included as the available data were not comprehensive
for all people receiving these treatments. Finally, the
National Bowel Screening Program commenced in
August 2006, screening people aged 55 and 65 years,
16 so
our results do not fully address what happens in the
presence of the screening programme. However, the
study is population-based, reasonably large and uses
reliable surgical information
24 and is an important
addition to the literature on the subject.
CONCLUSIONS
Despite considerable research on the delay between
screening and colonoscopy, the study is one of the ﬁrst
to examine the pathway following diagnosis and prior to
surgery. There do not appear to be systemic issues
affecting time from colonoscopy to surgery related to
patients’ socio-demographic characteristics. However,
a more systematic approach might be needed to ensure
that cancer patients are treated in specialist cancer
centres, particularly for cases requiring more specialised
treatment.
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